Can a drug switch after kidney transplant reduce Long-Term risks?
NCT ID NCT00811915
First seen Apr 15, 2026 · Last updated May 20, 2026 · Updated 6 times
Summary
This study looked at whether switching kidney transplant patients from tacrolimus to sirolimus (both with mycophenolate mofetil) could lower the risk of kidney damage, new diabetes, and cancer. It involved 65 stable transplant recipients between 12 and 36 months after surgery. The goal was to see if the switch improved safety while still protecting the transplanted kidney.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANTATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
UHAmiens
Amiens, France
-
UHAngers
Angers, 49933, France
-
UHCaen
Caen, 14000, France
-
UHLimoges
Limoges, France
-
UHNecker
Paris, 75015, France
-
UHRennes
Rennes, 35000, France
-
UHRouen
Rouen, 76000, France
-
UHTours
Tours, France
Conditions
Explore the condition pages connected to this study.